Dear Colleague,
Kinases, key drivers of malignant transformation and major contributors to a
variety of other human pathologies, have emerged as some of the most exciting
targets in drug discovery. However, with initial well documented success stories
came realization that many hurdles lie in the path of successful development of
new drugs, targeting kinase signaling. GTC’s 2nd Protein Kinases & Drug
Design Conference, to be held in October 23~25, 2013, San Diego, CA, will bring together
speakers representing world leading academic centers and pharmaceutical
companies to discuss how to overcome the many hurdles and answer exciting key
questions. Experts will also share their positive and negative experiences
on how predictive preclinical models are with clinical efficacy and toxicology.
Key Questions to be Discussed:
- What are the best approaches to identify key kinases
contributing to neurodegenerative diseases and major forms of human cancer
from leukemias and breast cancer to malignant gliomas?
- How do different factors, including genetic background,
interactions with stroma, “stemness” of the tumor cells contribute to tumor
responses to kinase inhibitors?
- What are the best computational, chemical biology and
structural biology approaches to de novo kinase drug design, including a
“holy grail” of kinase drug discovery - non-ATP competitive inhibitors?
- What is the right balance between inhibitor selectivity
and activity?
- Are covalent inhibitors a “no-no” in drug discovery?
- What have we learned from the use of the latest
generation of inhibitors, targeting many of the hottest pathways (PI3K,
Her2, CDKs, JNK) in pre-clinical models and clinical trials?
- How can we predict pharmacological properties of new
kinase inhibitors?
Preliminary
Sessions for 2013 Agenda:
I. Recent Advances
in Drug Design & Development
II. Selective vs Non-selective Kinases Inhibitors
III. Recent Advancements in Hit and Target Identification
IV. Novel Oncology Kinases & Inhibitors
V. Preclinical Models – How Predictive Are They?
IV. Kinase Targets in Pre-clinical and Clinical Trials
Call for Papers (Poster Presentation)!
To be
considered for a short oral presentation, please submit an abstract
here
by September 23, 2013. Selected presentations will be based on quality of
abstract and availability. Presentation slots fill up fast so please submit your
abstract ASAP.
Sponsorship and exhibiting opportunities are available in a range of levels,
which can be tailored to fit your needs. Please contact 626-256-6405 x102 or spex@gtcbio.com for
more information.
Best
regards,
Organizing
Committee
|
